MELINTA THERAPEUTICS INC (MLNT) Stock Price, Forecast & Analysis
NASDAQ:MLNT
MLNT Key Statistics, Chart & Performance
The current stock price of MLNT is 0.5 null. In the past month the price decreased by -68.15%. In the past year, price decreased by -90.57%.
MLNT Technical Analysis
MLNT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLNT. MLNT may be in some trouble as it scores bad on both profitability and health.
MLNT Financial Highlights
Over the last trailing twelve months MLNT reported a non-GAAP Earnings per Share(EPS) of -9.469999999999999. The EPS increased by 19.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -393.39% | ||
| ROA | -140.14% | ||
| ROE | N/A | ||
| Debt/Equity | -1.47 |
MLNT Forecast & Estimates
MLNT Ownership
About MLNT
Company Profile
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.
Company Info
MELINTA THERAPEUTICS INC
44 WHIPPANY ROAD
MORRISTOWN NJ 07960
CEO: John H. Johnson
Phone: 908-617-1309
MELINTA THERAPEUTICS INC / MLNT FAQ
Can you describe the business of MELINTA THERAPEUTICS INC?
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.
What is the stock price of MELINTA THERAPEUTICS INC today?
The current stock price of MLNT is 0.5 null. The price decreased by -5.7% in the last trading session.
Does MELINTA THERAPEUTICS INC pay dividends?
MLNT does not pay a dividend.
What is the ChartMill rating of MELINTA THERAPEUTICS INC stock?
MLNT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for MLNT stock?
MELINTA THERAPEUTICS INC (MLNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.47).
What is MELINTA THERAPEUTICS INC worth?
MELINTA THERAPEUTICS INC (MLNT) has a market capitalization of 6.88M null. This makes MLNT a Nano Cap stock.
What is the ownership structure of MELINTA THERAPEUTICS INC (MLNT)?
You can find the ownership structure of MELINTA THERAPEUTICS INC (MLNT) on the Ownership tab.